Ocumension Therapeutics Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Ocumension Therapeutics yıllık ortalama 50.6% oranında kazançlarını artırırken, Pharmaceuticals sektöründe kazançlar growing at 5.7% annual. Gelirler yılda ortalama 61.3% oranında büyüyor .

Anahtar bilgiler

50.6%

Kazanç büyüme oranı

92.5%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi	5.6%
Gelir büyüme oranı	61.3%
Özkaynak getirisi	-11.7%
Net Marj	-104.0%
Son Kazanç Güncellemesi	30 Jun 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Gelir ve Gider Dağılımı

Ocumension Therapeutics nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

SZSC:1477 Gelir, gider ve kazançlar (CNY Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Jun 24	310	-323	409	109
31 Mar 24	278	-351	416	117
31 Dec 23	246	-380	423	124
30 Sep 23	227	-399	429	141
30 Jun 23	208	-418	435	159
31 Mar 23	184	-411	405	172
31 Dec 22	159	-403	374	184
30 Sep 22	124	-393	340	180
30 Jun 22	90	-383	305	175
31 Mar 22	73	-322	279	172
31 Dec 21	56	-260	254	169
30 Sep 21	44	-426	237	194
30 Jun 21	32	-593	220	220
31 Mar 21	23	-1,429	252	200
31 Dec 20	13	-2,265	284	180
30 Sep 20	8	-2,540	242	150
30 Jun 20	2	-2,816	200	121
31 Mar 20	1	-2,064	130	110
31 Dec 19	0	-1,312	60	99

Kaliteli Kazançlar: 1477 şu anda kârlı değil.

Büyüyen Kar Marjı: 1477 şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: 1477 kârlı değildir, ancak son 5 yılda zararlarını yılda 50.6% oranında azaltmıştır.

Büyüme Hızlandırma: 1477 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: 1477 kârlı olmadığından, geçmiş yıl kazanç büyümesinin Pharmaceuticals sektörüyle ( 9.4% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: 1477 hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -11.66% ) sahiptir.

Ocumension Therapeutics Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

First half 2024 earnings released: CN¥0.23 loss per share (vs CN¥0.32 loss in 1H 2023)

Ocumension Therapeutics to Report First Half, 2024 Results on Aug 12, 2024

Full year 2023 earnings released: CN¥0.58 loss per share (vs CN¥0.64 loss in FY 2022)

Full year 2023 earnings released: CN¥0.59 loss per share (vs CN¥0.64 loss in FY 2022)

Ocumension Therapeutics to Report Fiscal Year 2023 Results on Mar 21, 2024

First half 2023 earnings released: CN¥0.32 loss per share (vs CN¥0.31 loss in 1H 2022)

Recent updates

Ocumension Therapeutics Announces Resignation of Yumeng Wang as Non-Executive Director

New minor risk - Shareholder dilution

Ocumension Therapeutics Announces New Drug Application of OT-502 Accepted by the National Medical Products Administration

Ocumension Therapeutics Announces New Drug Application of OT-1001 Approved by the National Medical Products Administration

New minor risk - Profitability

First half 2024 earnings released: CN¥0.23 loss per share (vs CN¥0.32 loss in 1H 2023)

Ocumension Therapeutics to Report First Half, 2024 Results on Aug 12, 2024

Ocumension Therapeutics Announces Biologic License Application for OT-702 Accepted by the National Medical Products Administration

Ocumension Therapeutics, Annual General Meeting, Jun 20, 2024

Full year 2023 earnings released: CN¥0.58 loss per share (vs CN¥0.64 loss in FY 2022)

Full year 2023 earnings released: CN¥0.59 loss per share (vs CN¥0.64 loss in FY 2022)

Ocumension Therapeutics Announces Phase II Clinical Trial of OT-202

Ocumension Therapeutics to Report Fiscal Year 2023 Results on Mar 21, 2024

Ocumension Therapeutics (SEHK:1477) commences an Equity Buyback for 69,071,128 shares, representing 10% of its issued share capital, under the authorization approved on June 16, 2023.

Ocumension Therapeutics Completes Enrollment in the Phase Iii Clinical Trial of OT-502 in China

Ocumension Therapeutics Completes Patient Enrollment in the Phase II Clinical Trial of OT-202 in China

Ocumension Therapeutics Announces Executive Changes, Effective September 30, 2023

New minor risk - Profitability

First half 2023 earnings released: CN¥0.32 loss per share (vs CN¥0.31 loss in 1H 2022)

Ocumension Therapeutics to Report First Half, 2023 Results on Aug 24, 2023

Ocumension Therapeutics Announces Clinical Trial Authorization for Initiating A Phase III Clinical Trial of Ot-101-S

Forecast to breakeven in 2025

Ocumension Therapeutics Completes Patient Enrollment in Globalmulti-Center Phase III Clinical Trial of OT-101

Full year 2022 earnings released: CN¥0.64 loss per share (vs CN¥0.43 loss in FY 2021)

Ocumension Therapeutics Provides Preliminary Unaudited Consolidated Group Earnings Guidance for the Year Ended December 31, 2022

No longer forecast to breakeven

Ocumension Therapeutics Provides Update on Phase I Clinical Trial of Ot-202

Ocumension Therapeutics Announces Patient Enrollment Complete in the Phase III Clinical Trial of OT-101 in China

Now 22% undervalued

Now 22% undervalued after recent price drop

Less than half of directors are independent

First half 2022 earnings released: CN¥0.31 loss per share (vs CN¥0.12 loss in 1H 2021)

Ocumension Therapeutics to Report First Half, 2022 Results on Aug 26, 2022

Board Member recently sold HK$246k worth of stock

Now 24% undervalued

Ocumension Therapeutics Receives Approval from the National Medical Products Administration for Yutio Chronic Non-Infectious Uveitis

EyePoint Pharmaceuticals, Inc. and OcuMension Therapeutics Announce Approval of New Drug Application by China's NMPA for YUTIQ(R) for the Treatment of Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye

Ocumension Therapeutics Announces Executive Changes

Ocumension Therapeutics Announces CDE Approval Received for A Phase III Clinical Trial of OT-703 in China

Ocumension Therapeutics Receives Approval from the National Medical Products Administration for its IND Application to Begin the Phase Iii Clinical Study for Fluocinolone Acetonide Intravitreal Implant

Less than half of directors are independent

Ocumension Therapeutics Appoints Mr. Zhenyu Zhang as Independent Non-Executive Director, the Chairman of the Remuneration Committee and a Member of the Nomination Committee and Audit Committee

Ocumension Therapeutics Announces Demise of Lianming HE, Independent Non-Executive Director, Chairman of the Remuneration Committee and Member of the Audit Committee and Nomination Committee

Forecast to breakeven in 2024

Full year 2021 earnings released: CN¥0.43 loss per share (vs CN¥7.49 loss in FY 2020)

Ocumension Therapeutics Voluntary Announcement primary Clinical Endpoint Achieved in the Phase III clinical Trial of OT-1001

Nicox’s Partner Ocumension Obtains Positive Phase 3 Clinical Trial Results for ZERVIATE® in China

Ocumension Therapeutics Announces First Patient Enrolled in the Clinical Trial of self-Developed Class I New Drug OT-202 in China

First half 2021 earnings released: CN¥0.12 loss per share (vs CN¥27.36 loss in 1H 2020)

Ocumension Therapeutics Receives CDE Approval for Commencement of a Phase III Clinical Trial OT-502 (DEXYCU®) in China

First half 2021 earnings released: CN¥0.12 loss per share (vs CN¥27.36 loss in 1H 2020)

Ocumension Therapeutics MHRA Approval Received for Phase III Clinical Trial of OT-101 in the United Kingdom

Ocumension Therapeutics Announces CDE Approval Received for A Phase III Clinical Trial of OT-101

Ocumension Therapeutics Announces Clinical Trial Authorization for Initiatinga Phase III Clinical Trial of OT-101 Accepted in United Kingdom

Ocumension Therapeutics Announces Investigational New Drug Application for Initiating A Multi-Regional Phase Iii Clinical Trial in the People's Republic of China for OT-101

Non-Executive Director has left the company

Ocumension Therapeutics Announces Board Changes

Ocumension Therapeutics, Annual General Meeting, Jun 29, 2021

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin